Literature DB >> 7105487

Spleen lymphocyte populations in patients with Hodgkin's disease--properties of cells with different densities.

B Rocha, A A Ferreira, G Munn, M de Sousa, A A Freitas.   

Abstract

Spleen lymphocytes from five patients with Hodgkin's disease (HD) type mixed cellularity and five normal controls were studied. An increased percentage of 'null cells' was observed in three out of the five patients studied. The two other patients had increased percentage of T lymphocytes. Lymphocytes from spleen with HD had a decreased ability to respond to suboptimal concentrations of T cell mitogens. When these cells were fractionated in a discontinuous density gradient a subpopulation of cells, unable to respond to Con A, was recovered from the dense cell fractions. The implications of the present findings to the understanding of the physiopathological changes in HD are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105487      PMCID: PMC1536462     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Response of human thymus-derived (T) and non-thymus-derived (B) lymphocytes to mitogenic stimulation in vitro.

Authors:  R S Geha; E Merler
Journal:  Eur J Immunol       Date:  1974-03       Impact factor: 5.532

2.  Functional heterogeneity of murine lymphoid cells. 3. Differential responsiveness of T cells to phytohemagglutinin and concanavalin A as a probe for T cell subsets.

Authors:  J D Stobo; W E Paul
Journal:  J Immunol       Date:  1973-02       Impact factor: 5.422

3.  Lymphocyte surface characteristics in malignant lymphoma.

Authors:  A C Aisenberg; J C Long
Journal:  Am J Med       Date:  1975-03       Impact factor: 4.965

4.  Letter: T and B lymphocytes in spleen in Hodgkin's disease.

Authors:  R R Joseph; D Belpomme
Journal:  Lancet       Date:  1975-03-29       Impact factor: 79.321

5.  Letter: Lymphocytes in spleen in Hodgkin's disease.

Authors:  V Grifoni; G S Del Giacco; P E Manconi; S Tognella; G Mantovani
Journal:  Lancet       Date:  1975-02-08       Impact factor: 79.321

6.  Impaired lymphocyte function in untreated Hodgkin's disease.

Authors:  R Levy; H S Kaplan
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

7.  Editorial: Systemic lupus erythematosus and type C RNA viruses.

Authors:  C L Christian
Journal:  N Engl J Med       Date:  1976-08-26       Impact factor: 91.245

8.  The selective elimination of immunologically competent cells from bone marrow and lymphocyte cell mixtures. 3. In vitro test for detection of immunocompetent cells in fractionated mouse spleen cell suspensions and primate bone marrow suspensions.

Authors:  K A Dicke; G Tridente; D W van Bekkum
Journal:  Transplantation       Date:  1969-10       Impact factor: 4.939

9.  Identification and characterization of subpopulations of lymphocytes in human peripheral blood after fractionation on discontinuous gradients of albumin. The cellular defect in X-linked agammaglobulinemia.

Authors:  R S Geha; F S Rosen; E Merler
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  3 in total

1.  Subsets of blood, spleen and recirculating lymphocytes in man.

Authors:  G Reinecke; R Pabst
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

2.  Evaluation of the circulating and splenic lymphocyte subpopulations in patients with non-Hodgkin lymphomas and Hodgkin's disease using monoclonal antibodies.

Authors:  F Herrmann; G Sieber; B Jauer; A Lochner; B Komischke; H Rühl
Journal:  Blut       Date:  1983-07

Review 3.  Lymphocyte migration in malignant disease.

Authors:  D Crowther; J Wagstaff
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.